Opus Genetics (IRD) Non-Current Deffered Revenue (2010 - 2018)
Opus Genetics' (IRD) quarterly Non-Current Deffered Revenue came in at $19900.0 in Q4 2018, down 94.69% year-on-year from $375000.0 in Q4 2017, and down 33.33% on a QoQ basis from $29850.0 in Q3 2018.
Opus Genetics (IRD) Non-Current Deffered Revenue (2010 - 2018) Analysis & Trends
Opus Genetics (IRD) has 9 years of Non-Current Deffered Revenue data on file, last reported at $19900.0 in Q4 2018.
- On a quarterly basis, Non-Current Deffered Revenue fell 94.69% year-over-year to $19900.0 in Q4 2018; TTM through Dec 2018 was $19900.0, a 94.69% decrease from a year earlier, with the FY2018 full-year figure at $19900.0, down 94.69% from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $19900.0, down from $29850.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for IRD reached as high as $782280.0 in Q1 2014 and fell as low as $19900.0 in Q4 2018.
- Historically, Non-Current Deffered Revenue has averaged $244258.7 across 5 years, with a median of $115444.0 in 2015.
- Across the five-year window, Non-Current Deffered Revenue surged 1408.66% in 2014 and tumbled 94.69% in 2018, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $129710.0 in 2014, then dropped by 19.81% to $104020.0 in 2015, then dropped by 23.86% to $79204.0 in 2016, then surged by 373.46% to $375000.0 in 2017, then tumbled by 94.69% to $19900.0 in 2018.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $19900.0 in Q4 2018, $29850.0 in Q3 2018, and $39575.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 19,900.00 |
| Sep 30, 2018 | 29,850.00 |
| Jun 30, 2018 | 39,575.00 |
| Mar 31, 2018 | 48,150.00 |
| Dec 31, 2017 | 375,000.00 |
| Sep 30, 2017 | 61,557.00 |
| Jun 30, 2017 | 65,812.00 |
| Mar 31, 2017 | 431,250.00 |
| Dec 31, 2016 | 79,204.00 |
| Sep 30, 2016 | 468,750.00 |
| Jun 30, 2016 | 450,000.00 |
| Mar 31, 2016 | 98,308.00 |
| Dec 31, 2015 | 104,020.00 |
| Sep 30, 2015 | 543,750.00 |
| Jun 30, 2015 | 115,444.00 |
| Mar 31, 2015 | 120,199.00 |
| Sep 30, 2014 | 129,710.00 |
| Jun 30, 2014 | 678,156.00 |
| Mar 31, 2014 | 782,280.00 |
| Dec 31, 2013 | 129,564.00 |